GNFTF News and Press, Genfit Ord From 04/19/23

Lille ( France ) ; Cambridge ( Massachusetts, United States ) ; Zurich (Switzerland) ; April 19 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with sev...

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); April 18 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe ch...

Cash, cash equivalents and current financial assets totaled €140.2 million 1 as of December 31, 2022, expected to fund operations through third quarter 2024 Transformative milestone expected towards end of second quarter 2023, with topline data readout for Phase 3 ELATI...

Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutic...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized ...

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized b...

The following slide deck was published by Genfit SA in conjunction with this event. For further details see: Genfit (GNFT) Investor Presentation - Slideshow

Genfit SA (GNFT) Q4 2021 Earnings Conference Call April 8, 2022 8:00 a.m. ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - Chief Executive Officer Tom Baetz - Chief Financial Officer Dean Hum - Chief Scientific Officer Carol Addy - Chief Medical Office...

Genfit press release (NASDAQ:GNFT): FY GAAP EPS of €1.23. Revenue of €85.58M (+1002.8% Y/Y). Cash and cash equivalents totaled €258.8 million as of December 31, 202. Outlook 2022: Elafibranor in Primary Biliary Cholangitis, commitment for topline data reado...